DNA ploidy analysis as an adjunct for the detection of relapse in B-lineage acute lymphoblastic leukemia

References

• DeVita V T, Hellman S, Rosenberg S A. Cancer: Principles and Practice of Oncology. Lippincott, Philadelphia 2001; 3235
   Google Scholar
• Pizzo P A, Poplack D G. Principles and Practice of Pediatric Oncology. Lippincott, Philadelphia 2002; 1712
   Google Scholar
• Reiter A, Schrappe M, Ludwig W D, Hiddemann W, Sauter S, Henze G, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Blood 1994; 84: 3122–3133
   PubMed Web of Science ®Google Scholar
• Veerman A JP, Hahlen K, Kamps W A, Van Leeuwen E F, De Vaan G A, Solbu G, et al. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia: results of protocol ALLVI from the Dutch childhood leukemia study group. J Clin Oncol 1996; 14: 911–918
   PubMed Web of Science ®Google Scholar
• Childhood ALL Collaborative Group (CACG). Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukemia: overview of 42 trials involving 12000 randomized children. Lancet 1996; 347: 1783–1788
   PubMed Web of Science ®Google Scholar
• Coustan-Smith E, Sancho J, Hancock M L, Boyett J M, Behm F G, Ribeiro R C, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000; 96: 2691–2696
   PubMed Web of Science ®Google Scholar
• Vora A, Frost L, Goodeve A, Wilson G, Ireland R M, Lilleyman J, et al. Late relapsing childhood lymphoblastic leukemia. Blood 1998; 92: 2334–2337
   PubMed Web of Science ®Google Scholar
• Cave H, Van Der Werff Ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. N Engl J Med 1998; 339: 591–598
   PubMed Web of Science ®Google Scholar
• Leitenberg D, Rappeport J M, Smith B R. B-cell precursor bone marrow reconstitution after bone marrow transplantation. Am J Clin Pathol 1994; 102: 231–236
   PubMed Web of Science ®Google Scholar
• Van Dongen J JM, Seriu T, Panzer-Grumayer E R, Biondi A, Pongers-Willemse M J, Corral L, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia of childhood. Lancet 1998; 352: 1731–1738
   PubMed Web of Science ®Google Scholar
• Gameiro P, Moreira I, Yetgin S, Papaioannou M, Potter M N, Prentice H G, et al. Polymerase chain reaction (PCR)- and reverse transcription PCR-based minimal residual disease detection in long-term follow-up of childhood acute lymphoblastic leukaemia. Br J Haematol 2002; 119: 685–696
   PubMed Web of Science ®Google Scholar
• Eckert C, Biondi A, Seeger K, Cazzaniga G, Hartmann R, Beyermann B, et al. Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet 2001; 358: 1239–1241
   PubMed Web of Science ®Google Scholar
• Gruhn B, Hongeng S, Yi H, Hancock M L, Rubnitz J E, Neale G A, et al. Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome. Leukemia 1998; 12: 675–681
   PubMed Web of Science ®Google Scholar
• Roberts W M, Estrov Z, Ouspenskaia M V, Johnston D A, McClain K L, Zipf T F. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. N Engl J Med 1997; 336: 317–323
   PubMed Web of Science ®Google Scholar
• Goulden N J, Knechtli C JC, Garland R J, Langlands K, Hancock J P, Potter M N, et al. Minimal residual disease analysis for the prediction of relapse in children with standard-risk acute lymphoblastic leukaemia. Br J Haematol 1998; 100: 235–244
   PubMed Web of Science ®Google Scholar
• DeHaas V, Oosten L, Dee R, Verhagen O JHM, Kroes W, van den Berg H, et al. Minimal residual disease studies are beneficial in the follow-up of TEL/AML1 patients with B-precursor acute lymphoblastic leukaemia. Br J Haematol 2000; 111: 1080–1086
   PubMed Web of Science ®Google Scholar
• Borowitz M J, Pullen D J, Shuster J J, Viswanatha D, Montgomery K, Willman C L, et al. Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group Study. Leukemia 2003; 17: 1566–1572
   PubMed Web of Science ®Google Scholar
• Dworzak M N, Froschl G, Printz D, Mann G, Potschger U, Muhlegger N, et al. Prognostic significance of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood 2002; 99: 1952–1958
   PubMed Web of Science ®Google Scholar
• Vidriales M, Perez J J, Lopez-Berges M C, Gutierrez N, Ciudad J, Lucio P, et al. Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value. Blood 2003; 101: 4695–4700
   PubMed Web of Science ®Google Scholar
• Coustan-Smith E, Behm F G, Sanchez J, Boyett J M, Hancock M L, Raimondi S C, et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 1998; 351: 550–554
   PubMed Web of Science ®Google Scholar
• Farahat N, Morilla A, Owusu-Ankomah K, Morilla R, Pinkerton C R, Treleaven J G, et al. Detection of minimal residual disease in B-lineage acute lymphoblastic leukaemia by quantitative flow cytometry. Br J Haematol 1998; 101: 158–164
   PubMed Web of Science ®Google Scholar
• Bruggemann M, Raff T, Flohr T, Gokbuget N, Nakao M, Droese J, et al. Clinical significance of minimal residual disease quantification in adult patients with standard risk acute lymphoblastic leukemia. Blood 2006; 107: 1116–1123
   PubMed Web of Science ®Google Scholar
• Krampera M, Perbellini O, Vincenzi C, Zampieri F, Pasini A, Scupoli M T, et al. Methodological approach to minimal residual disease detection by flow cytometry in adult B-lineage acute lymphoblastic leukemia. Haematologica 2006; 91: 1109–1112
   PubMed Web of Science ®Google Scholar
• Campana D. Determination of minimal residual disease in leukaemia patients. Br J Haematol 2003; 121: 823–838
   PubMed Web of Science ®Google Scholar
• Dworzak M N, Fritsch G, Panzer-Grumayer E R, Mann G, Gadner H. Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping: method and significance. Leuk Lymphoma 2000; 38: 295–308
   PubMed Web of Science ®Google Scholar
• Weir E G, Cowan K, LeBeau P, Borowitz M J. A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection. Leukemia 1999; 13: 558–567
   PubMed Web of Science ®Google Scholar
• Gaipa G, Basso G, Maglia O, Leoni V, Faini A, Cazzaniga G, et al. Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection. Leukemia 2005; 19: 49–56
   PubMed Web of Science ®Google Scholar
• Borowitz M J, Pullen D J, Winick N, Martin P L, Bowman W P, Camitta B. Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: a report from the Childrens Oncology Group. Cytometry Part B 2005; 68: 18–24
   PubMedGoogle Scholar
• Kerst G, Kreyenberg H, Roth C, Well C, Dietz K, Coustan-Smith E, et al. Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukemia by flow cytometry and real time PCR. Br J Haematol 2005; 128: 774–785
   PubMed Web of Science ®Google Scholar
• Zehentner B K, Fritschle W, Stelzer T, Ghirardelli K M, Hunter K, Wentzel C, et al. Minimal disease detection and confirmation in hematologic malignancies: combining cell sorting with clonality profiling. Clin Chem 2006; 52: 430–437
   PubMed Web of Science ®Google Scholar
• Campana D, Coustan-Smith E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry 1999; 38: 139–152
   PubMedGoogle Scholar
• Heerema N A, Sather H N, Sensel M G, Zhang T, Hutchinson R J. Prognostic impact of trisomies of chromosomes 10, 17, and 5 among children with acute lymphoblastic leukemia and high hyperdiploidy (>50 chromosomes). J Clin Oncol 2000; 18: 1876–1887
   PubMed Web of Science ®Google Scholar
• Raimondi S C. Current status of cytogenetic research in childhood acute lymphoblastic leukemia. Blood 1993; 70: 2237–2251
   Google Scholar
• Pui C H, Carroll A J, Raimondi S C, Land V J, Crist W M, Shuster J J, et al. Clinical presentation, karyotypic characterization, and treatment outcome of childhood acute lymphoblastic leukemia with a near-haploid or hypodiploid less than 45 line. Blood 1990; 75: 1170–1177
   PubMed Web of Science ®Google Scholar
• Heerema N A, Nachman J B, Sather H N, Sensel M G, Lee M K, Hutchinson R, et al. Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 1999; 94: 4036–4045
   PubMed Web of Science ®Google Scholar
• Almeida J, Orfao A, Ocqueteau M, Mateo G, Corral M, Caballero M D, et al. High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma. Br J Haematol 1999; 107: 121–131
   PubMed Web of Science ®Google Scholar
• Orfao A, Ciudad J, Gonzalez M, Lopez A, del Mar Abad M, Paz Bouza J I, et al. Flow cytometry in the diagnosis of cancer. Scand J Clin Lab Invest Suppl 1995; 221: 145–152
   PubMedGoogle Scholar
• Tomova A, Babusikova O. Shifts in expression of immunological cell markers in relapsed acute leukemia. Neoplasma 2001; 48: 164–168
   PubMed Web of Science ®Google Scholar
• Tsurusawa M, Kaneko Y, Katano N, Niwa M, Ito M, Fujimoto T. Flow cytometric evidence for minimal residual disease and cytological heterogeneities in acute lymphoblastic leukemia with severe hypodiploidy. Am J Hematol 1989; 32: 42–49
   PubMed Web of Science ®Google Scholar
• Zhang R, Yao E. Significance of FCM-DNA measurement in detecting minimal residual disease in leukemia. Chin Med J 1990; 103: 826–830
   PubMed Web of Science ®Google Scholar
• Nowak R, Oelschlaegel U, Hofmann R, Zengler H, Huhn R. Detection of aneuploid cells in acute lymphoblastic leukemia with flow cytometry before and after therapy. Leuk Res 1994; 18: 897–901
   PubMed Web of Science ®Google Scholar
• Nowak R, Oelschlaegel U, Schuler U, Zengler H, Hofmann R, Ehninger G, et al. Sensitivity of combined DNA/Immunophenotype flow cytometry for the detection of low levels of aneuploid lymphoblastic leukemia in cells in bone marrow. Cytometry 1997; 30: 47–53
   PubMedGoogle Scholar
• Zwick D, Cooley L, Hetherington M. Minimal residual disease testing of acute leukemia by flow cytometry immunophenotyping: a retrospective comparison of detection rates with flow cytometry DNA ploidy or FISH-based methods. Lab Hematol 2006; 12: 75–81
   PubMedGoogle Scholar